Want to see KR:302440 full AI Analyst Report?
Top Page
SK bioscience Co.,Ltd.
(302440)
Select Model
Select Model
Rating:43Neutral
Price Target:
$30,639.00
Action:N/A
Date:10/28/26
The score is held down primarily by weak financial performance (steep TTM revenue contraction, ongoing losses, and heavy negative free cash flow) and bearish technical momentum (trading below key moving averages with negative MACD). A still-healthy equity cushion and moderate leverage prevent an even lower score, but valuation remains constrained by loss-making results and no dividend support.
Positive Factors
Integrated Vaccine Capabilities
An integrated presence across vaccine R&D, clinical development, manufacturing and distribution gives the company control across the product lifecycle. Its mix of routine, preventive and pandemic-response vaccines can support multiple demand channels and preserve strategic relevance beyond one product.
Negative Factors
Severe Revenue Contraction
The extreme TTM revenue contraction indicates that recent commercial performance has weakened materially rather than merely fluctuating around a stable base. Sustained losses following earlier profitability raise execution risk and make it harder to support development spending, fixed costs and durable earnings recovery.
Read all positive and negative factors
Positive Factors
Negative Factors
Integrated Vaccine Capabilities
An integrated presence across vaccine R&D, clinical development, manufacturing and distribution gives the company control across the product lifecycle. Its mix of routine, preventive and pandemic-response vaccines can support multiple demand channels and preserve strategic relevance beyond one product.
Read all positive factors
SK bioscience Co.,Ltd. (302440) vs. SPDR S&P 500 ETF (SPY)
Market Cap
₩2.52T
Dividend YieldN/A
Average Volume (3M)59.98K
Price to Earnings (P/E)―
Beta (1Y)0.32
Revenue Growth23.25%
EPS Growth-58.35%
CountryKR
Employees984
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-1066.27
Shares Outstanding78,456,550
10 Day Avg. Volume75,621
30 Day Avg. Volume59,978
Financial Highlights & Ratios
PEG Ratio-25.96
Price to Book (P/B)2.11
Price to Sales (P/S)5.79
P/FCF Ratio-46.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-882.32
Revenue Forecast (FY)₩690.59B
SK bioscience Co.,Ltd. Business Overview & Revenue Model
Company Description
SK bioscience Co.,Ltd. is a pharmaceutical firm focused on the discovery, development, production, and worldwide commercialization of vaccines and other biopharmaceutical products. Its current range of marketed vaccines includes Skycellflu, a cell...
SK bioscience Co.,Ltd. Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
63
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 659.27B | 651.37B | 267.55B | 369.51B | 456.73B | 929.00B |
| Gross Profit | 66.82B | 59.49B | 30.98B | 141.82B | 239.61B | 570.28B |
| EBITDA | -125.65B | -60.31B | -36.20B | 43.49B | 171.43B | 493.00B |
| Net Income | -79.34B | -56.17B | -53.88B | 22.32B | 122.45B | 355.14B |
Balance Sheet | ||||||
| Total Assets | 2.98T | 2.96T | 2.84T | 1.85T | 2.14T | 2.11T |
| Cash, Cash Equivalents and Short-Term Investments | 832.60B | 906.30B | 1.16T | 1.27T | 1.48T | 1.65T |
| Total Debt | 543.37B | 469.99B | 392.81B | 20.57B | 113.34B | 106.24B |
| Total Liabilities | 974.91B | 918.29B | 821.14B | 148.58B | 400.23B | 508.81B |
| Stockholders Equity | 1.75T | 1.79T | 1.80T | 1.70T | 1.74T | 1.60T |
Cash Flow | ||||||
| Free Cash Flow | -162.23B | -80.58B | -300.24B | -20.95B | -201.45B | 492.12B |
| Operating Cash Flow | 911.03M | 102.51B | -128.02B | 29.35B | -124.96B | 536.59B |
| Investing Cash Flow | -210.29B | -361.76B | 53.56B | -45.28B | 272.65B | -1.42T |
| Financing Cash Flow | 84.96B | 41.60B | 252.48B | -89.58B | -19.87B | 958.38B |
SK bioscience Co.,Ltd. Technical Analysis
Negative
―
Price Trends
36499.00
Negative
36528.50
Negative
40817.50
Negative
Market Momentum
-1088.50
Positive
32.05
Neutral
7.71
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:302440, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 35502.50, equal to the 50-day MA of 36499.00, and equal to the 200-day MA of 40817.50, indicating a bearish trend. The MACD of -1088.50 indicates Positive momentum. The RSI at 32.05 is Neutral, neither overbought nor oversold. The STOCH value of 7.71 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:302440.
SK bioscience Co.,Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | ₩613.71B | 13.10 | ― | 0.49% | 51.28% | 124.70% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
45 Neutral | ₩253.61B | -2.70 | ― | ― | 84.72% | -480.97% | |
43 Neutral | ₩2.52T | -30.15 | ― | ― | 23.25% | -58.35% | |
43 Neutral | ₩291.21B | -16.97 | ― | ― | 116.74% | -482.50% | |
41 Neutral | ₩48.51B | -0.23 | ― | ― | -64.38% | 10.38% |
* General Sector Average
KR:302440
SK bioscience Co.,Ltd.
32,150.00
-18,750.00
-36.84%
KR:005690
Pharmicell Co., Ltd
10,230.00
-6,961.53
-40.49%
KR:011000
GeneOne Life Science, Inc.
2,670.00
-7,680.00
-74.20%
KR:064550
Bioneer Corporation
7,070.00
-7,410.00
-51.17%
KR:199800
ToolGen Incorporated
29,800.00
-26,559.59
-47.13%
KR:950210
Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh
4,220.00
-8,460.00
-66.72%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.